Given its role in cancer progression, several EGFR inhibitors (EGFRIs) have been developed in the form of monoclonal antibodies, namely cetuximab (Erbitux®) and panitumumab (Vectibix®), as well as in the form of small-molecule drugs such as erlotinib (Tarceva®) and gefitinib (Iressa®). Here, EGFR is linked to cancer.